Dr. Reddy's Laboratories Ltd.: US Court Prevents Dr. Reddy's Laboratories from Selling Drugs for the Treatment of Opioid Dependence

NEW DELHI: The actions of Dr. Reddy's Laboratories will be finalized Monday morning after the New Jersey District Court granted a preliminary injunction against the national drug manufacturer to sell a generic version of the drug Suboxone. Indivior in the US market. treatment of opioid dependence.

The court prevented Dr. Reddy from relaunching his generic product until Indivior's patent litigation was concluded or until it was over. overrides an appeal of this injunction, according to Shaun Thaxter, CEO of Indivior.

Dr. Reddy was selling a generic product on the US market prior to the granting of a Temporary Restriction Order (TRO) on June 15. The TRO remains in place, notes Indivior.

The court also ordered the parties to submit a final injunction injunction on Monday. He asked Indivior to send a bond to ensure the safety of Dr. Reddy if the court concluded at the end of the patent litigation that the patent is invalid or not infringed.

Indivior expects a $ 25 million decline in its revenues as a result of the sale of the product by Dr. Reddy before the coming into effect of the TRO.